Health
UK regulator approves retifanlimab for advanced, inoperable anal cancer
The MHRA has licensed retifanlimab (ZYNYZ) with carboplatin and paclitaxel for adults with inoperable squamous cell carcinoma of the anal canal that has spread or recurred, granting approval on 5 November 2026.